Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that 50 percent of the planned total number of participants have been randomized in the Phase 3 RELIEF trial, a potential pivotal study of TNX-102 SL* (cyclobenzaprine HCl sublingual tablets) 5.6 mg, a non-opioid, centrally acting analgesic, taken daily at bedtime for the management of fibromyalgia. An interim analysis of the first 50 percent of randomized participants will be conducted shortly after the 12-week treatment period has been completed by these participants.

Southern Research is collaborating with a New York pharma company on the development of a coronavirus vaccine

Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will be conducting a virtual presentation in conjunction with the Planet MicroCap Showcase Virtual Investor Conference on Wednesday, April 22, 2020, at 12:00 p.m. ET. In addition, Dr. Lederman will participate in a MicroCap Investing Workshop panel discussion titled, “Potential Solutions for Addressing the Coronavirus Pandemic,” scheduled from 10:30 a.m. – 11:30 a.m. ET, Tuesday, April 21, 2020. A live webcast and subsequent archived recording of both the Company’s virtual presentation and panel discussion will be available under the IR Events tab of the Investor Relations section of the Tonix website at www.tonixpharma.com.

Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today a strategic collaboration with Southern Research to support the development of a vaccine, TNX-1800* (live modified horsepox virus vaccine for percutaneous administration) to protect against the new coronavirus disease, COVID-19, based on Tonix’s proprietary horsepox vaccine platform. Tonix is developing TNX-801 (live horsepox virus vaccine for percutaneous administration) as a potential smallpox preventing vaccine for the U.S. strategic national stockpile and as a monkeypox preventing vaccine. The Company believes that its proprietary horsepox virus has the potential to serve as a vector for vaccines to protect against other infectious agents.

NEW YORK, May 07, 2020 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, and the University of Alberta,.

Four Potential Vaccines in Development to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on the Company’s Horsepox Virus Vaccine Platform Potential Vaccine,.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 6) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...

This offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-224586) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). A prospectus supplement relating to the shares of common stock will be filed by Tonix with the SEC. When available, copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or from A.G.P./Alliance Global Partners, 590 Madison Avenue, 36th Floor, New York, New York 10022 or by email at prospectus@allianceg.com.

The outbreak of COVID-19 caused by the new coronavirus SARS-CoV-2 is roiling the global economy. The pandemic has caused more than 6,500 deaths, according to Johns Hopkins University. About 35 vaccine candidates with different modes of action are in development for COVID-19, according to the World Health Organization. The following are coronavirus vaccine candidates in development along with the sponsor, vaccine type and stage of development:Inovio Pharmaceuticals Inc (NASDAQ: INO) * Type of Vaccine: DNA plasmid vaccine * Stage of Development: PreclinicalInovio has received funding from multiple agencies for developing INO-4800 and an intradermal delivery device for the vaccine. An accelerated timeline provided by the company points toward INO-4800 entering clinics by April. The company hopes to make available 1 million doses of the vaccine by end of 2020.Applied DNA Sciences Inc (NASDAQ: APDN) & Takis Biotech * Type of Vaccine: Linear DNA vaccine * Stage of Development: PreclinicalAfter revealing Feb. 7 plans to expand an existing collaboration for a polymerase chain reaction-produced linear DNA, Applied DNA said March 2 the companies have designed four vaccine candidates for preclinical testing. Takis will likely begin animal testing in the second quarter of 2020.Johnson & Johnson's (NYSE: JNJ) Janssen Unit * Type of Vaccine: non-replicating viral vector * Stage of Development: PreclinicalJ&J said Feb. 11 it is expanding collaboration with Biomedical Advanced Research and Development Authority, or BARDA, with the latter providing funding for accelerated development of the vaccine candidate.J&J said the vaccine program will leverage Janssen's AdVac and PER.C6 technologies to rapidly upscale production of optimal vaccine candidates. J&J has the experience of working on similar vaccine candidates for viral threats such as Zika and Ebola.The company said last week that it has entered into a collaboration with the Beth Israel Deaconess Medical Center to support development of a vaccine for COVID-19. The company and hospital have embarked on preclinical testing of multiple vaccine prospects, targeting the shortlisting of one by the end of March and initiation of a Phase 1 clinical study of by the end of 2020. Altimmune Inc (NASDAQ: ALT) * Type of Vaccine: non-replicating viral vector * Stage of Development: PreclinicalAltimmune said in late February said it has completed the design and synthesis of a novel single-dose intranasal vaccine using its proprietary technology to protect against COVID-19. The vaccine candidate is based on the same platform as its influenza vaccine candidate NasoVAX, according to the company. Altimmune said it expects to begin clinical testing as early as August.See also: How Close Are Biotechs To Bringing A COVID-19 Treatment To Market? Novavax, Inc. (NASDAQ: NVAX) * Type of Vaccine: nanoparticle vaccine * Stage of Development: PreclinicalNovavax is evaluating multiple nanoparticle vaccine candidates in animal models, the company said Wednesday in its fourth-quarter earnings report. It also plans to use its proprietary Matrix-M adjuvant with its vaccine candidate to enhance immune responses.The company expects to begin Phase 1 testing in May or June. Novavax said it has received an initial funding award of $4 million from CEPI and is in talks to secure additional funding.Moderna Inc (NASDAQ: MRNA) * Type of Vaccine: mRNA * Stage of Development: PreclinicalModerna created a splash early on when it said Feb. 24 that it has shipped vials of MRNA-1273 to the National Institute of Allergy and Infectious Diseases to be used in a planned Phase 1 study in the U.S.The company said it delivered the vaccine candidate from its cGMP facility in 42 days after sequence selection.There has been no further update from either the company or NIAID on the start of clinical trials.Vaxart Inc (NASDAQ: VXRT) * Type of Vaccine: oral vaccine * Stage of Development: PreclinicalVaxart said in late January it plans to generate vaccine candidates based on the published genome of the new coronavirus and evaluate these in preclinical models.BioNTech SE - ADR (NASDAQ: BNTX) * Type of Vaccine: mRNA * Stage of Development: PreclinicalBioNTech said it plans to start clinical testing of its vaccine candidate BNT162 for COVID-19 in late April. It also announced a partnership with Fosun Pharma to develop the vaccine in China and said it is in talks with Pfizer Inc. (NYSE: PFE) regarding development of the vaccine outside China.Other Companies, Institutions Working On Coronavirus * GlaxoSmithKline plc (NYSE: GSK) and the Chinese biotech Clover Biopharma: Clover's protein based vaccine candidate S-Trimer is to be tested with Glaxo's pandemic adjuvant system (preclinical testing). * Sanofi SA (NASDAQ: SNY): working with BARDA to develop a COVID-19 vaccine using its recombinant DNA platform (preclinical testing). * Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) with Southern Research: TNX-1800, a modified version of its Tonix's horsepox virus vaccine for subcutaneous administration (preclinical testing). * Geovax Labs Inc (OTC: GOVX) and Wuhan, China-based BravoVax: GeoVax is using its GV-MVA-VLP vaccine platform to design and construct vaccine candidates using genetic sequences from COVID-19 virus (preclinical testing). * Arcturus Therapeutics Ltd (NASDAQ: ARCT): The company is working with the Duke-NUS Medical School in Singapore to develop a vaccine candidate using its proprietary Self-Transcribing and Replicating RNA technology (preclinical testing). * University of Oxford: The university is working with Italian manufacturer Advent Srl to produce the first batch of a vaccine candidate codenamed ChAdOx1 nCoV-19 for clinical testing (preclinical testing). * CureVac: The company said March 3 it is selecting the most suitable mRNA vaccine candidates from several constructs and it is also coordinating with the German Paul Ehrlich Institute for accelerated clinical development of these candidate. The company expects to start clinical trials in early summer.Related Links: How The COVID-19 Outbreak Is Benefiting Biotech Investors See more from Benzinga * The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings * The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today the pricing of an underwritten public offering with expected total gross proceeds of $7.5 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) 3,837,000 Class A Units, each Class A Unit consisting of one share of common stock, par value $0.001 per share (the “Common Stock”) and one Warrant (the “Warrants”) to purchase one share of common stock at a price of $0.57 per Class A Unit and (ii) 5,313 Class B Units, each consisting of one share of Series B Preferred Stock (the “Preferred Stock”) with a stated value of $1,000 per share and convertible into 1,754.386 shares of common stock together with Warrants to purchase 1,754.386 shares of common stock at a combined price of $1,000 per Class B Unit.

Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will be conducting a virtual presentation in conjunction with the Spring Investor Summit on Wednesday, March 25, 2020, at 1:50 p.m. ET. A live webcast and subsequent archived recording of the Company’s virtual presentation will be available under the IR Events tab of the Investor Relations section of the Tonix website at www.tonixpharma.com. In 2020, Tonix announced a program to develop a potential vaccine, TNX-1800* (live modified horsepox virus vaccine for percutaneous administration) to protect against the novel coronavirus disease emerging in 2019, or COVID-19.

Potential Vaccine, TNX-1800 in Development to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on the Company’s Horsepox Virus Vaccine Platform Potential Vaccine,.

Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Herbert Harris, M.D., Ph.D., as its new Executive Vice President, Translational Medicine, effective May 15, 2020. In this role, Dr. Harris will focus on advancing Tonix’s pre-clinical pipeline, including the potential COVID-19 vaccine into the clinic, as well as participate in Tonix’s ongoing clinical programs.

The Company sold 14,550,000 shares of common stock at $1.10 per share. Following the offering, the Company had an aggregate of 49,227,634 shares of common stock outstanding. This offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-224586) previously filed with the U.S. Securities and Exchange Commission (the “SEC”).

Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today the closing of its previously announced underwritten public offering with total gross proceeds of approximately $7,500,000 before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) 3,837,000 Class A Units, each Class A Unit consisting of one share of common stock, par value $0.001 per share (the “Common Stock”) and one Warrant (the “Warrants”) to purchase one share of common stock at a price of $0.57 per Class A Unit and (ii) 5,313 Class B Units, each consisting of one share of Series B Preferred Stock (the “Preferred Stock”) with a stated value of $1,000 per share and convertible into 1,754.386 shares of common stock and one Warrant to purchase 1,754.386 shares of common stock at a combined price of $1,000 per Class B Unit.

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 5.) Alector Inc (NASDAQ: ALEC ) (announced granting ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 25) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) (Cowen ...

NEW YORK, May 21, 2020 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, posted two posters for the.

Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that the Company has decided to stop enrollment in the Phase 3 RECOVERY study of Tonmya# or TNX-102 SL* (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of posttraumatic stress disorder (PTSD) following an unblinded, pre-specified interim analysis by the Independent Data Monitoring Committee (IDMC). Based on interim analysis results of the first 50% of enrolled participants, the IDMC recommended stopping the trial for futility as Tonmya is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall change from baseline in the severity of PTSD symptoms, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) between those treated with Tonmya and those receiving placebo.